Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
- Status
- COMPLETED
- Phase
- PHASE1
Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy
- Status
- COMPLETED
- Phase
- PHASE1
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE2
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients
- Status
- TERMINATED
- Phase
- PHASE2
Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)
- Status
- RECRUITING
- Phase
- PHASE2
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2